Pedersen, Terje

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 2,479

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 801

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal

Lipoproteins and Cardiovascular HealthBlood Pressure and Hypertension Studies

Cited by 676

Cholesterol-Lowering Therapy in Women and Elderly Patients With Myocardial Infarction or Angina Pectoris: Findings From the Scandinavian Simvastatin Survival Study (4S)

Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J., & Group, F. T. S. S. S. (1997) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 508

Smoking and adverse outcomes in patients with CKD: The Study of Heart and Renal Protection (SHARP)

Staplin, N., Haynes, R., Herrington, W. G., Reith, C., Cass, A., Fellström, B., Jiang, L., Kasiske, B. L., Krane, V., Levin, A., et al. (2016) · American Journal of Kidney Diseases

Smoking Behavior and CessationChronic Kidney Disease and Diabetes

Cited by 86

Editorial

Sniderman, A. D., Pedersen, T., & Kjekshus, J. (1997) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 57

Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)

Arsenault, B. J., Boekholdt, S. M., Mora, S., DeMicco, D. A., Bao, W., Tardif, J.-C., Amarenco, P., Pedersen, T., Barter, P., & Waters, D. D. (2014) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthCardiac Valve Diseases and Treatments

Cited by 36

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection

on behalf of the SHARP Collaborative Group, Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., et al. (2017) · BMC Nephrology

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 16